Apixaban in patients with atrial fibrillation and impaired renal function - subanalysis of ARISTOTLE study
2013
Abstract
Patients with atrial fibrillation and concomitant renal insufficiency are at an increased risk of thromboembolic and bleeding complications. Oral factor Xa inhibitor apixaban, which has a low degree of renal excretion is therefore an attractive therapeutic option for this population.
The predefined secondary analysis of patients with kidney disease in a study ARISTOTLE apixaban was superior to warfarin in preventing stroke, systemic embolism, total mortality and major bleeding regardless of the degree of renal impairment.